Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:35 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Local Methotrexate Injections for the Treatment of Nail Psoriasis
NCT06578728 · Weill Medical College of Cornell University · PHASE4 · terminated · last registry update 2026-06-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated due to slow accrual.” | – | Registry record, Weill Medical College of Cornell University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NR3C1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Phase 3 first posted: Ain Shams University, Trimetazidine + Standard Treatment (NCT07916922)
- 2026-11-04Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, a drug against NR3C1 (NCT07915037)
- 2026-10-27Phase 3 first posted: The George Institute, Fludrocortisone 50 mcg daily + Fludrocortisone 100 mcg daily (NCT07898462)
- 2026-10-15Results posted on the registry: St. Jude Children's Research Hospital, CPX-351 + MHA (NCT05656248)
- 2026-10-02Also stopped (suspended): Columbia University, Steroid Injection (NCT03722303)
- 2026-10-01Phase 3 first posted: ECOG-ACRIN Cancer Research Group, Abiraterone Acetate + Cabazitaxel (NCT07852195)
- 2026-09-29Also stopped (suspended): University of Washington, Asparaginase Erwinia chrysanthemi + Cyclophosphamide (NCT06738368)
- 2026-09-18Results posted on the registry: Embera NeuroTherapeutics, Inc., Metyrapone + Oxazepam (NCT00567814)
- 2026-09-14Also stopped (withdrawn): Neurocrine UK Limited, Chronocort® + Standard Care (NCT03532022)
- 2026-08-31Also stopped (withdrawn): CAMC Health System, Hydrocortisone + Fludrocortisone (NCT00368381)
- 2026-08-11Results posted on the registry: Wake Forest University Health Sciences, Cyclophosphamide + Doxorubicin Hydrochloride (NCT03505762)
- 2026-08-06Results posted on the registry: Cristcot HCA LLC, Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator + Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator (NCT04469686)
- 2026-07-30Also stopped (terminated): M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT03488225)
- 2026-07-28Also stopped (terminated): Siriraj Hospital, Early hydrocortisone + Normal saline placebo (NCT06217939)
- 2026-07-24Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cyclophosphamide (NCT07724457)
- 2026-07-23Results posted on the registry: University of Colorado, Denver, a drug against NR3C1 (NCT04606966)
- 2026-07-22Results posted on the registry: Academic and Community Cancer Research United, Acalabrutinib + Bortezomib (NCT04626791)
- 2026-07-22Also stopped (terminated): Mayo Clinic, Abiraterone Acetate/Niraparib + Prednisone (NCT05689021)
- 2026-07-10Results posted on the registry: University of California, Los Angeles, a drug against NR3C1 (NCT05191030)
- 2026-07-07Also stopped (withdrawn): Vastra Gotaland Region, OD dual-release Hydrocortisone + TID Hydrocortisone (NCT05716607)
- 2026-06-30Results posted on the registry: The University of Texas Medical Branch, Galveston, Betamethasone + Placebo (NCT02939742)
- 2026-06-30Also stopped (terminated): The University of Texas Medical Branch, Galveston, Betamethasone + Placebo (NCT02939742)
- 2026-06-25Phase 3 first posted: Peking Union Medical College Hospital, Prednisone + Compound betamethasone (NCT07668895)
- 2026-06-15Also stopped (withdrawn): University Hospital, Tours, Prednisone + Hydrocortisone (NCT04359511)
- 2026-06-12Also stopped (withdrawn): Rennes University Hospital, a drug against NR3C1 (NCT03688789)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision